EU GMP Annex 1 Explained: Environmental Monitoring & Bioburden Control in Practice
In this on-demand webinar, Johannes Oberdörfer explores environmental monitoring and bioburden control requirements under the updated EU GMP Annex 1, with practical guidance for pharmaceutical QC laboratories. Learn how Annex 1 expectations impact contamination control strategies, risk-based monitoring programs, and continuous improvement in GMP environments.
Suggested videos
Learn more about Rapid Micro Biosystems Growth Direct
Rapid Micro Biosystems · 3:27
EU GMP Annex 1 Explained [2026]: A Comprehensive Overview of Sterile Drug Manufacturing | GMP CQV
GMP GUIDE · 8:01
Learn how Rapid Micro Biosystems is Contributing Toward the Clean Facility of the Future
Rapid Micro Biosystems · 3:01
What You Need to Know About the EU GMP Annex 1 Revision
Pharmatech Associates, a USP company · 59:57
The Growth Direct™ System
Rapid Micro Biosystems · 4:39
EU GMP ANNEX 1: Complete Document Explained
GMP GUIDE · 29:13
EU GMP Annex 1 — Quality Control: Microbial Expertise, Bioburden and Parametric Release | Part 10A
Pharma Best Practices · 9:35
My Insight on Rapid Micro Biosystems' Annual Report Takeaways
Corporate Decoder · 8:18
The Impact of Annex 1 and Your Contamination Control Strategy
Thomas Scientific · 31:28
S03E392 #LiveWithChaudhrey w Rapid Micro Biosystems #30 Johannes Oberdörfer at #PharmaCongress Day 1
RSK Life Science Media · 3:33
EU GMP Annex 1 — The Architecture of Sterility Assurance
Pharma Best Practices · 12:03
My Key Concern from Rapid Micro Biosystems' Quarterly Filing
Corporate Decoder · 7:34